Krishna Institute Of Medical Sciences Limited · NSE:KIMS
Krishna Institute Of Medical Sciences — Q4 FY24 Earnings Presentation
32 slides from Krishna Institute Of Medical Sciences's earnings presentation, May 16, 2024
Slide 1: Cover letter to stock exchanges: Investor Presentation
16th May 2024 The General Manager, The Manager, Department of Corporate Services Listing Department Bombay Stock Exchange Ltd (BSE) National Stock Exchange of India Limited, Phiroze Jheejheebhoy Towers, Exchange Plaza, 5th Floor, Dalal Street, Plot No.C/1, 'G' Block, Mumbai - 400 001. Bandra - Kurla
Slide 2: Q4 FY24 Update
Q4 FY24 UPDATE Private & Confidential
Slide 3: Driven by a Vision
Driven by a Vision Affordable Quality Care VISION: Best-in-Class Facilities Patient Centric Systems & Processes S To be the most preferred NT healthcare services brand by TIE providing affordable care and best PA clinical outcomes to patients. Clinical Outcome Driven Excellence And to be the best pl
Slide 4: Multi Specialty Care
Multi Specialty Care Brain Eyes Bones and Spine Radiology • Neurology • Ophthalmology • Orthopedics • Imaging • Neurosurgery Gastro Intestinal Tract • Arthroscopic Surgery • Interventional Radiology • Psychiatry • Medical Gastroenterology • Spine Surgery Lab Services • Neuro Rehabilitation • Surgica
Slide 5: KIMS at a Glance
KIMS at a Glance Telangana Secunderabad (1000) Maharashtra Paradise Circle (290) (Shifted to Begumpet) Nagpur (334) Kondapur (200) Nashik (Under Construction) Gachibowli (237) Thane (Under Construction) Andhra Pradesh Visakhapatnam (469) Srikakulam (200) Rajahmundry (195) Karnataka Ongole (350) Beng
Slide 6: Dr. B. Bhaskar Rao - Visionary Behind KIMS
Dr. B. Bhaskar Rao - Visionary Behind KIMS Chairman & Managing Director A legend in CT Surgery, Dr. Bollineni Bhaskar Rao {MBBS, MS, DNB (CT Surgery)} is one of the very few Cardio- Thoracic Surgeons in the country, who performed over 30000 surgeries in his career spanning over more than 25 years. W
Slide 7: Dr. Abhinay Bollineni
Dr. Abhinay Bollineni Chief Executive Officer Dr. Abhinay Bollineni joined KIMS Hospitals in 2013 and spent the next couple of years in Hospital Operations before taking charge of Strategy & Marketing for the Group in 2015. In a short span of 5 years, KIMS expanded and opened five additional units (
Slide 8: Board of Directors
Board of Directors Dr. Bhaskara Rao Bollineni Dr. Abhinay Bollineni Mrs. Anitha Dandamudi Mr. Saumen Chakraborty Chairman & Managing Director Chief Executive Officer Whole-time Director Independent Director, Chairman (Audit Committee) Mr. Adwik Bollineni Mr. Venkata Ramudu Jasthi Mrs. Y. Prameela Ra
Slide 9: Shareholding Pattern - As on 31 March, 2024
Shareholding Pattern - As on 31 March, 2024 st Retail & Others, Retail Pre IPO, 3.7% 7.3% Promoter & Promoter Share Holder No of Shares Share Holding % Category Group, 38.8% Promoter 3,10,51,304 38.8% ICICI Ventures 7,75,758 1.0% Sbi Mf 57,42,961 7.2% DII FII, 16.6% Axis Mf 38,49,750 4.8% DII Hdfc M
Slide 10: Modern Medical Technology
Modern Medical Technology 4-Arm HD da Vinci O-Arm Scanner Spy Glass Fibroscan Robotic Surgical Multi-dimensional surgical State of the art add on to Specialized non-invasive System imaging platform optimized ERCP that allows doctors to diagnostic ultrasound-based Facilitates complex for use in spine
Slide 11: Many Firsts...
Many Firsts... • First in Asia in to do Trans catheter • India’s first COVID Double Lung • Number 1 in Nephrology treatments in Tricuspid Valve replacement transplant done in 2020 Andhra Pradesh* procedure done in 2018 • India’s first Breathing Lung transplant • Number 1 in Neurosurgery & Poly • Lar
Slide 12: Key Accomplishments
Key Accomplishments NAL ACCRED ATIO IT N AT ER ION INT QU Y ET LI AF A TY & PAT I E N T S Pharmacie De Qualite (PDQ) American Accreditation Commission Certification Overall PDQ Evaluation ‘Best Patient Friendly Hospital’ Ranked No. 1 Hospital International (AACI) Performance Score - 98% AHPI Health
Slide 13: Consistent Performer over 2 decades
Consistent Performer over 2 decades (Rupees in Millions) 25,112 6,232 22,235 5,766 % .1% : 2 7.1 16,711 : 3 0 5,217 R CAG GR CA 11,287 2,412 4,280 773 1,311 317 263 42 2005 2010 2015 2020 2022 2023** 2024 2005 2010 2015 2020 2022*** 2023** 2024 No. of No. of No. of No. of No. of No. of No. of Hospit
Slide 14: Q4 FY24 Updates
Q4 FY24 Updates 13 Private & Confidential
Slide 15: Financial & Operational Highlights - 1/2
Financial & Operational Highlights - 1/2 (Rupees in Millions) FINANCIAL HIGHLIGHTS Q4 FY 24 Consolidated • Gross revenue at INR 6376 Mn, an increase of 9.8% on YoY and 4.7% on QoQ basis. • EBITDA of INR 1628 Mn, a decline of 3.2% on YoY and growth by 8.3% on QoQ basis. • EBITDA margin in Q4FY24 stoo
Slide 16: Financial & Operational Highlights - 2/2
Financial & Operational Highlights - 2/2 OPERATIONAL Q4 FY 24 Consolidated HIGHLIGHTS • ARPOB grew by 11.5% and 12.1% on QoQ and YoY basis respectively • ARPP grew by 7.0% and 7.5% on QoQ and YoY basis respectively • Conducted 4.1 lakhs OPD consults in Q4 FY24, grown by 7.9% on YoY and 4.9% on QoQ b
Slide 17: Digital & ESG Initiatives
Digital & ESG Initiatives DIGITAL KIMS continued to evolve 100% paperless for clinical workflows. As part of this initiative, KIMS delivered the following features in its EHR INITIATIVES application: • Dialysis Module • Corp OPD Module • OPD Enhancements • IP Module • ER Module • ICU - Fluid Chart •
Slide 18: Group Operating Performance - 1/2
Group Operating Performance - 1/2 IP VOLUME (‘000) OP VOLUME (‘000) 7.9% (2.3%) 8.6% 4.9% 191 47 1,588 411 177 45 46 1,462 392 381 137 1,014 FY22 FY23 FY24 Q4 FY23 Q3 FY24 Q4 FY24 FY22 FY23 FY24 Q4 FY23 Q3 FY24 Q4 FY24 OCCUPANCY* ARPOB (‘000) (2.8%) 6.6% 11.5% 58.5% 1.5% 54.3% 31.9 34.3 53.2% 51.4%
Slide 19: Group Operating Performance - 2/2
Group Operating Performance - 2/2 Particulars FY22 FY23 FY24 Q4 FY23 Q3 FY24 Q4 FY24 Bed Capacity 3,064 3,940 3,975 3,940 3,975 3,975 Operational Beds 2,590 3,468 3,503 3,468 3,503 3,503 Census Beds 2,246 2,960 2,989 2,960 2,989 2,989 Non Census Beds 344 508 514 508 514 514 Occupied Beds 1,793 2,071
Slide 20: Group Financial Performance
Group Financial Performance (Rupees in Millions) TOTAL REVENUE EBITDA 12.9% 4.7% 3.7% 8.2% 25,112 6,376 6,535 1,681 1,628 22,235 6,091 6,299 1,504 5,808 5,361 16,711 FY22 FY23 FY24 Q4 FY23 Q3 FY24 Q4 FY24 FY22 FY23 FY24 Q4 FY23 Q3 FY24 Q4 FY24 PBT* (2.2%) (2.4%) PAT* (4.2%) (6.5%) 4,701 1,273 3,510
Slide 21: Operational and Financial Performance - 1/2
Operational and Financial Performance - 1/2 KIMS Telangana (KIMS) Andhra Pradesh (KIMS) Particulars FY22 FY23 FY24 Q4 FY23 Q3 FY24 Q4 FY24 FY22 FY23 FY24 Q4 FY23 Q3 FY24 Q4 FY24 Bed Capacity 1,200 1,200 1,200 1,200 1,200 1,200 1864 1879 1,914 1879 1914 1,914 Operational Beds 1,035 1,085 1,085 1,085
Slide 22: Operational and Financial Performance - 2/2
Operational and Financial Performance - 2/2 Sunshine, Nagpur & Group Sunshine Nagpur Group Particulars FY23 FY24 Q4 FY23 Q3 FY24 Q4 FY24 FY23** FY24 Q4 FY23 Q3 FY24 Q4 FY24 FY22 FY23 FY24 Q4 FY23 Q3 FY24 Q4 FY24 Bed Capacity 527 527 527 527 527 334 334 334 334 334 3,064 3,940 3,975 3,940 3,975 3,975
Slide 23: Speciality Mix
Speciality Mix Others Cardiac Science 22% 18% Renal Sciences 9% Mother & Child 9% Group FY24 Organ Oncology Transplant 6% 3% Gastric Sciences 8% Neuro Sciences 11% Orthopaedics 14% 22 Private & Confidential
Slide 24: Payor & Cluster Profile
Payor & Cluster Profile PAYOR MIX CLUSTER TOTAL REVENUE Maharashtra 7% Andhra Pradesh Aarogyasri 27% 7% Cash Telangana Corporate Group 66% 13% 53% FY24 Group FY24 CLUSTER EBITDA Maharashtra Insurance 4% 27% Andhra Pradesh 23% Group Telangana 73% FY24 1) Telengana - Secunderad , Kondapur, Begumpet &
Slide 25: Key Achievements in Q4 FY24
Key Achievements in Q4 FY24 24 Private & Confidential
Slide 26: Key Achievements in Q4 FY24
Key Achievements in Q4 FY24 25 Private & Confidential
Slide 27: Key to our success
Key to our success Doctor Affordable Partnerships Quality Care Modern Medical Infra 26 Private & Confidential
Slide 28: KIMS has a disciplined growth strategy in adjacent markets
KIMS has a disciplined growth strategy - strategically grow in adjacent markets some of which are ‘natural extensions’ KIMS Plans to Grow into Markets that are Adjacent to the Current Core Markets of AP and Telangana Central & Western India (Mumbai, Indore, Aurangabad, Nagpur & Raipur): KIMS flagshi
Slide 29: Expansion plans
Expansion plans Current Incremental Approx. Expected Year of Units New Departments Beds Beds Capex Operation Nashik - 300 All Specialities 200-250 Cr Q1 FY25 Mumbai (Thane) - 300 All Specialities 500-525 Cr Q4 FY25 Bangalore (Project-1) - 415 All Specialities 350-400 Cr Q4 FY25 Anantapur 250 200 Can
Slide 30: Profit and Loss Statement
Profit and Loss Statement (Rupees in Millions) Consolidated Particulars Q4 FY 23 Q3 FY 24 Q4 FY 24 QoQ(%) YoY(%) FY 23 FY 24 YoY(%) Operating Revenue 5,759 6,058 6,338 4.6% 10.0% 21,977 24,981 13.7% Other Income 49 32 38 18.4% -21.6% 259 131 -49.5% Total Revenue 5,808 6,091 6,376 4.7% 9.8% 22,236 25
Slide 31: Corporate Structure (As on 31 March'24)
Corporate Structure (As on 31 March'24) st Krishna Institute of Medical Sciences Limited KIMS Secunderabad KIMS Nellore KIMS Rajahmundry KIMS Ongole (100%) (100%) (100%) (100%) AHPL KHEPL KIMS ICON KIMS Saveera KIMS Sunshine KIMS-Manavata SPANV KIMS Hospitals Srikakulam Kondapur Visakhapatnam Ananta
Slide 32: Thank You
Thank You 31 Private & Confidential
Krishna Institute of Medical Sciences — Q4 FY24 Earnings Presentation on 6ix